Big Pharma Split Corp Class A (PRM) - Net Assets
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has net assets worth CA$13.14 Million CAD (≈ $9.51 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$25.77 Million ≈ $18.64 Million USD) and total liabilities (CA$12.62 Million ≈ $9.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$13.14 Million |
| % of Total Assets | 51.01% |
| Annual Growth Rate | -4.35% |
| 5-Year Change | 3.77% |
| 10-Year Change | N/A |
| Growth Volatility | 29.63 |
Big Pharma Split Corp Class A - Net Assets Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A's net assets have evolved over time, based on quarterly financial data. See PRM defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Big Pharma Split Corp Class A (2017–2024)
The table below shows the annual net assets of Big Pharma Split Corp Class A from 2017 to 2024. For live valuation and market cap data, see Big Pharma Split Corp Class A stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$13.68 Million ≈ $9.90 Million |
-13.68% |
| 2023-12-31 | CA$15.85 Million ≈ $11.47 Million |
-19.66% |
| 2022-12-31 | CA$19.73 Million ≈ $14.27 Million |
-11.93% |
| 2021-12-31 | CA$22.40 Million ≈ $16.21 Million |
+69.92% |
| 2020-12-31 | CA$13.19 Million ≈ $9.54 Million |
-19.16% |
| 2019-12-31 | CA$16.31 Million ≈ $11.80 Million |
-13.45% |
| 2018-12-31 | CA$18.84 Million ≈ $13.63 Million |
+0.89% |
| 2017-12-31 | CA$18.68 Million ≈ $13.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Big Pharma Split Corp Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$13.68 Million | 100.00% |
| Total Equity | CA$13.68 Million | 100.00% |
Big Pharma Split Corp Class A Competitors by Market Cap
The table below lists competitors of Big Pharma Split Corp Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ostasiatiske Kompagni A/S
CO:OKEAC
|
$11.89 Million |
|
Aterian Inc
NASDAQ:ATER
|
$11.91 Million |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
$11.91 Million |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
$11.91 Million |
|
Wise Group AB
ST:WISE
|
$11.89 Million |
|
New Era Helium Inc Common Stock
NASDAQ:NEHC
|
$11.87 Million |
|
Armlogi Holding Corp. Common Stock
NASDAQ:BTOC
|
$11.87 Million |
|
TS Corp Preference Shares
KO:001795
|
$11.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Big Pharma Split Corp Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,850,981 to 13,682,674, a change of -2,168,307 (-13.7%).
- Net loss of 538,624 reduced equity.
- Dividend payments of 1,503,778 reduced retained earnings.
- Share repurchases of 469,119 reduced equity.
- New share issuances of 1,948,271 increased equity.
- Other factors decreased equity by 1,605,057.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-538.62K | -3.94% |
| Dividends Paid | CA$1.50 Million | -10.99% |
| Share Repurchases | CA$469.12K | -3.43% |
| Share Issuances | CA$1.95 Million | +14.24% |
| Other Changes | CA$-1.61 Million | -11.73% |
| Total Change | CA$- | -13.68% |
Book Value vs Market Value Analysis
This analysis compares Big Pharma Split Corp Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.98x to 1.13x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$13.73 | CA$13.52 | x |
| 2018-12-31 | CA$13.93 | CA$13.52 | x |
| 2019-12-31 | CA$13.64 | CA$13.52 | x |
| 2020-12-31 | CA$13.24 | CA$13.52 | x |
| 2021-12-31 | CA$17.38 | CA$13.52 | x |
| 2022-12-31 | CA$13.07 | CA$13.52 | x |
| 2023-12-31 | CA$13.03 | CA$13.52 | x |
| 2024-12-31 | CA$11.93 | CA$13.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Big Pharma Split Corp Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.13%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.92x
- Recent ROE (-3.94%) is below the historical average (10.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 1.73% | 79.39% | 0.01x | 1.74x | CA$-1.54 Million |
| 2018 | 14.75% | 86.01% | 0.10x | 1.78x | CA$895.79K |
| 2019 | 35.77% | 239.67% | 0.09x | 1.67x | CA$4.20 Million |
| 2020 | 2.01% | 45.04% | 0.03x | 1.74x | CA$-1.05 Million |
| 2021 | 21.66% | 90.56% | 0.14x | 1.69x | CA$2.61 Million |
| 2022 | 15.94% | 84.77% | 0.09x | 1.98x | CA$1.17 Million |
| 2023 | -0.88% | -44.80% | 0.01x | 1.67x | CA$-1.72 Million |
| 2024 | -3.94% | -29.13% | 0.07x | 1.92x | CA$-1.91 Million |
Industry Comparison
This section compares Big Pharma Split Corp Class A's net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $869,663,042
- Average return on equity (ROE) among peers: 9.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Big Pharma Split Corp Class A (PRM) | CA$13.14 Million | 1.73% | 0.96x | $11.89 Million |
| Aberdeen International Inc. (AAB) | $52.57 Million | 31.52% | 0.07x | $3.49 Million |
| Base Carbon Inc. (BCBN) | $103.01 Million | -28.06% | 0.09x | $52.58 Million |
| Canadian Banc Corp (BK) | $184.35 Million | 1.73% | 0.92x | $562.96 Million |
| Brookfield Corporation (BN) | $4.18 Billion | 6.97% | 0.79x | $102.06 Billion |
| Sprott Physical Gold and Silver Trust (CEF) | $1.24 Billion | 17.63% | 0.00x | $8.19 Billion |
| Canadian General Investments Ltd (CGI) | $533.40 Million | 17.99% | 0.28x | $795.13 Million |
| CI Financial Corp (CIX) | $1.61 Billion | 15.20% | 0.87x | $3.32 Billion |
| Clairvest Group Inc. (CVG) | $447.69 Million | 11.62% | 0.19x | $752.17 Million |
| Cymbria Corporation (CYB) | $317.74 Million | 0.50% | 0.02x | $1.01 Billion |
| Dividend 15 Split Corp II (DF) | $26.96 Million | 20.05% | 1.90x | $163.92 Million |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.